Base de dados : MEDLINE
Pesquisa : C04.557.435.135 [Categoria DeCS]
Referências encontradas : 271 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 271 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28834809
[Au] Autor:Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
[Ad] Endereço:Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
[Ti] Título:High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
[So] Source:Am J Surg Pathol;41(11):1513-1522, 2017 Nov.
[Is] ISSN:1532-0979
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Müllerian adenosarcoma harbors low malignant potential, except in cases with myometrial invasion or sarcomatous overgrowth. The presence of a high-grade stromal component has been proposed as an important pathologic predictor of outcome. We hypothesized that high-grade adenosarcoma has distinct clinical and molecular features, distinct from low-grade adenosarcoma. We analyzed the clinicopathologic features and follow-up of 9 high-grade adenosarcomas and a control group of 9 low-grade adenosarcomas. Comprehensive genomic analysis of the high-grade group was performed targeting exons of 409 oncogenes and tumor suppressor genes. In 1 case, the high-grade and low-grade components were separately sequenced. High-grade and low-grade adenosarcomas were comparable in patient age, myometrial invasion, and stage at presentation. Sarcomatous overgrowth was observed in 2/9 (22%) low-grade and 8/9 (89%) high-grade adenosarcomas. Six of 9 (67%) patients with high-grade adenosarcoma developed rapid recurrence; 1 died of her disease. Conversely, no low-grade tumors recurred or metastasized. Sequencing of high-grade adenosarcomas revealed frequent TP53 pathway alterations, identified in 7/9 (78%) cases. p53 expression by immunohistochemistry highly correlated with mutation status. Copy number variations occurred at a mean of 28.8 per tumor; most frequently involved genes included CDK4, MDM2, GNAS, SGK1, and DICER1. High-grade adenosarcoma is an aggressive neoplasm with propensity for short-interval recurrence and metastasis. The proportion of copy number alterations is similar to that reported for adenosarcoma with sarcomatous overgrowth. However, the high frequency of TP53 abnormalities is a novel finding, indicating that high-grade adenosarcoma is a distinct subset with driver TP53 pathway alterations. p53 immunohistochemistry can be used to confirm the presence of a high-grade component. Given its aggressive potential, the presence of any high-grade component in an adenosarcoma should be reported, even in the absence of sarcomatous overgrowth.
[Mh] Termos MeSH primário: Adenossarcoma/genética
Adenossarcoma/secundário
Biomarcadores Tumorais/genética
Mutação
Proteína Supressora de Tumor p53/genética
Neoplasias Uterinas/genética
Neoplasias Uterinas/patologia
[Mh] Termos MeSH secundário: Adenossarcoma/mortalidade
Adenossarcoma/terapia
Adulto
Idoso
Biomarcadores Tumorais/análise
Biópsia
Estudos de Casos e Controles
Cromograninas
Quinase 4 Dependente de Ciclina
RNA Helicases DEAD-box
Variações do Número de Cópias de DNA
Análise Mutacional de DNA
Progressão da Doença
Feminino
Subunidades alfa Gs de Proteínas de Ligação ao GTP
Dosagem de Genes
Perfilação da Expressão Gênica
Predisposição Genética para Doença
Seres Humanos
Proteínas Imediatamente Precoces
Imuno-Histoquímica
Meia-Idade
Gradação de Tumores
Recidiva Local de Neoplasia
Fenótipo
Proteínas Serina-Treonina Quinases
Proteínas Proto-Oncogênicas c-mdm2
Ribonuclease III
Fatores de Tempo
Resultado do Tratamento
Proteína Supressora de Tumor p53/análise
Neoplasias Uterinas/mortalidade
Neoplasias Uterinas/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Chromogranins); 0 (Immediate-Early Proteins); 0 (TP53 protein, human); 0 (Tumor Suppressor Protein p53); EC 2.3.2.27 (MDM2 protein, human); EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); EC 2.7.11.1 (serum-glucocorticoid regulated kinase); EC 2.7.11.22 (CDK4 protein, human); EC 2.7.11.22 (Cyclin-Dependent Kinase 4); EC 3.1.26.3 (DICER1 protein, human); EC 3.1.26.3 (Ribonuclease III); EC 3.6.1.- (Gnas protein, mouse); EC 3.6.4.13 (DEAD-box RNA Helicases); EC 3.6.5.1 (GTP-Binding Protein alpha Subunits, Gs)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1097/PAS.0000000000000907


  2 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28424089
[Au] Autor:Lee YJ; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, South Korea.
[Ti] Título:Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience.
[So] Source:World J Surg Oncol;15(1):87, 2017 Apr 19.
[Is] ISSN:1477-7819
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We aimed to evaluate the efficacy and the safety of uterine preservation in patients with early-stage uterine adenosarcoma who want to preserve future fertility. METHODS: We performed a retrospective review of patients with stage I uterine adenosarcoma diagnosed and treated at a single institute from 1998 through 2014. RESULTS: Among the total of 31 patients, uterine preservation surgery was performed in 7 of the nulliparas. Of the 7 patients receiving uterine preservation surgery, 3 showed no evidence of disease (NED), 2 had persistent disease confined to the uterus, and 2 were alive with disease (AWD) after recurrence. One patient with an NED status had a vaginal delivery at term. In the uterine preservation group, 1 patient had sarcomatous overgrowth at the time of diagnosis and experienced disease recurrence. In the hysterectomy group, 3 of 24 patients had tumor recurrence. Of the five patients with tumor recurrence, four (80%) had sarcomatous overgrowth at diagnosis and it was significantly associated with recurrence by univariate analysis (OR 13.3, p = 0.027). CONCLUSIONS: Uterine preservation represents a possible treatment option for young female patients who want to maintain fertility. However, a detailed explanation of the risk of recurrence is necessary, especially in patients with sarcomatous overgrowth, which seems to be associated with a higher risk of recurrence. TRIAL REGISTRATION: Retrospectively registered.
[Mh] Termos MeSH primário: Adenossarcoma/cirurgia
Preservação da Fertilidade/métodos
Procedimentos Cirúrgicos em Ginecologia/métodos
Recidiva Local de Neoplasia/cirurgia
Preservação de Órgãos/métodos
Tratamentos com Preservação do Órgão/métodos
Neoplasias Uterinas/cirurgia
[Mh] Termos MeSH secundário: Adenossarcoma/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos de Viabilidade
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Recidiva Local de Neoplasia/patologia
Estadiamento de Neoplasias
Prognóstico
Estudos Retrospectivos
Neoplasias Uterinas/patologia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.1186/s12957-017-1137-0


  3 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28382794
[Au] Autor:Lim MC; Lee M; Shim SH; Nam EJ; Lee JY; Kim HJ; Lee YY; Lee KB; Park JY; Kim YH; Ki KD; Song YJ; Chung HH; Kim S; Lee JW; Kim JW; Bae DS; Lee JM
[Ad] Endereço:Gynecologic Cancer Branch, Center for Uterine Cancer, and Center for Clinical Trials, Research Institute and Hospital and Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
[Ti] Título:Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.
[So] Source:J Gynecol Oncol;28(3):e22, 2017 May.
[Is] ISSN:2005-0399
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:Clinical practice guidelines for gynecologic cancers have been developed by academic society from several countries. Each guideline reflected their own insurance system and unique medical environment, based on the published evidence. The Korean Society of Gynecologic Oncology (KSGO) published the first edition of practice guidelines for gynecologic cancer treatment in late 2006; the second edition was released in July 2010 as an evidence-based recommendation. The Guidelines Revision Committee was established in 2015 and decided to develop the third edition of the guidelines in an advanced format based on evidence-based medicine, embracing up-to-date clinical trials and qualified Korean data. These guidelines cover strategies for diagnosis and treatment of primary and recurrent cervical cancer. The committee members and many gynecologic oncologists derived key questions through discussions, and a number of relevant scientific literature were reviewed in advance. Recommendations for each specific question were developed by the consensus conference, and they are summarized here, along with the details. The objective of these practice guidelines is to establish standard policies on issues in clinical practice related to the management in cervical cancer based on the results in published papers to date and the consensus of experts as a KSGO Consensus Statement.
[Mh] Termos MeSH primário: Adenossarcoma/diagnóstico
Adenossarcoma/terapia
Consenso
Recidiva Local de Neoplasia/terapia
Neoplasias Epiteliais e Glandulares/terapia
Neoplasias do Colo do Útero/diagnóstico
Neoplasias do Colo do Útero/terapia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Recidiva Local de Neoplasia/diagnóstico
República da Coreia
Sociedades Médicas
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.3802/jgo.2017.28.e22


  4 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28109626
[Au] Autor:Machida H; Nathenson MJ; Takiuchi T; Adams CL; Garcia-Sayre J; Matsuo K
[Ad] Endereço:Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA 90089, USA.
[Ti] Título:Significance of lymph node metastasis on survival of women with uterine adenosarcoma.
[So] Source:Gynecol Oncol;144(3):524-530, 2017 Mar.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Uterine adenosarcoma (UAS) is a rare gynecologic malignancy and the significance of lymph node metastasis on survival has not been well studied. METHODS: A retrospective study was performed utilizing the Surveillance, Epidemiology, End Results Program to examine UAS (n=994), endometrial stromal sarcoma (ESS, n=2910), and uterine leiomyosarcoma (LMS, n=5506) diagnosed between 1973 and 2013. The impact of lymph node metastasis on cause-specific survival (CSS) was cross-compared by multivariable analysis. Systematic literature review was conducted to examine the impact of nodal metastasis on progression-free survival (PFS) in UAS. RESULTS: UAS had the lowest incidence of lymph node metastasis among the sarcoma subtypes examined (UAS 2.9%, LMS 3.4%, and ESS 6.6%, P<0.001). Lymph node metastasis was independently associated with decreased CSS in all three tumor types (all, P<0.01); however, magnitudes of statistical significance of lymph node metastasis for CSS were similar across the three tumor types: adjusted-hazard ratio (aHR) for UAS 2.34, ESS 2.43, and LMS 2.10. Systematic literature review identified 230 unique cases of surgically treated UAS. On multivariable analysis, lymph node metastasis (aHR 4.72) had the greatest degree of significance for PFS compared to other tumor factors including sarcomatous overgrowth (aHR 2.88), heterologous elements (aHR 2.08), and deep myometrial invasion (aHR 1.51). Large tumor, deep myometrial invasion, and sarcomatous overgrowth were associated with increased risk of lymph node metastasis (all, P<0.05). CONCLUSION: While uterine adenosarcoma had a low incidence of lymph node metastasis, the impact of lymph node metastasis on survival was comparable to ESS or LMS.
[Mh] Termos MeSH primário: Adenossarcoma/mortalidade
Adenossarcoma/patologia
Linfonodos/patologia
Neoplasias Uterinas/mortalidade
Neoplasias Uterinas/patologia
[Mh] Termos MeSH secundário: Intervalo Livre de Doença
Feminino
Seres Humanos
Meia-Idade
Metástase Neoplásica
Estudos Retrospectivos
Programa de SEER
Análise de Sobrevida
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170123
[St] Status:MEDLINE


  5 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27923317
[Au] Autor:Özgü E; Narin MA; Yalçin HR; Tasçi T; Güngör T; Çavusoglu D; Meydanli MM; Tulunay G
[Ad] Endereço:a Department of Gynaecologic Oncology , Zekai Tahir Burak Women Health Education and Research Hospital , Ankara , Turkey.
[Ti] Título:Uterine adenosarcomas: A dual-institution experience.
[So] Source:J Obstet Gynaecol;37(1):93-96, 2017 Jan.
[Is] ISSN:1364-6893
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:There has been limited literature about treatment and follow-up strategies of uterine adenosarcomas because of their rare nature. For this study we retrospectively investigated the medical database of the two major womens' health hospitals in Turkey. A total of 15 patients were identified from the hospital's database. Median follow-up was 86.43 months for all patients. Seven out of 15 patients had recurrences during their follow-up. Among these 7 patients, 4 of them had stage IA disease. Median Disease Free Survival (DFS) and Overall Survival (OS) were calculated as 41.47 and 57.21 months, respectively. According to our study, polypoid tumours confined to the uterus with superficial myometrial invasion can be treated without comprehensive surgical staging. We believe that, publishing all the data in an organised manner even though they are small in size, gives us an opportunity to design meta-analysis for the development of more appropriate treatment strategies.
[Mh] Termos MeSH primário: Adenossarcoma/patologia
Neoplasias Uterinas/patologia
[Mh] Termos MeSH secundário: Adenossarcoma/mortalidade
Adenossarcoma/cirurgia
Bases de Dados Factuais
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Invasividade Neoplásica
Recidiva Local de Neoplasia
Estadiamento de Neoplasias
Estudos Retrospectivos
Resultado do Tratamento
Turquia
Neoplasias Uterinas/mortalidade
Neoplasias Uterinas/cirurgia
Útero/patologia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161208
[St] Status:MEDLINE
[do] DOI:10.1080/01443615.2016.1228619


  6 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27894165
[Au] Autor:Lee SW; Lee TS; Hong DG; No JH; Park DC; Bae JM; Seong SJ; Shin SJ; Ju W; Lee KH; Lee YK; Cho H; Lee C; Paek J; Kim HJ; Lee JW; Kim JW; Bae DS
[Ad] Endereço:Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
[Ti] Título:Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.
[So] Source:J Gynecol Oncol;28(1):e12, 2017 Jan.
[Is] ISSN:2005-0399
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:Clinical practice guidelines for gynecologic cancers have been developed by many organizations. Although these guidelines have much in common in terms of the practice of standard of care for uterine corpus cancer, practice guidelines that reflect the characteristics of patients and healthcare and insurance systems are needed for each country. The Korean Society of Gynecologic Oncology (KSGO) published the first edition of practice guidelines for gynecologic cancer treatment in late 2006; the second edition was released in July 2010 as an evidence-based recommendation. The Guidelines Revision Committee was established in 2015 and decided to produce the third edition of the guidelines as an advanced form based on evidence-based medicine, considering up-to-date clinical trials and abundant qualified Korean data. These guidelines cover screening, surgery, adjuvant treatment, and advanced and recurrent disease with respect to endometrial carcinoma and uterine sarcoma. The committee members and many gynecologic oncologists derived key questions from the discussion, and a number of relevant scientific literatures were reviewed in advance. Recommendations for each specific question were developed by the consensus conference, and they are summarized here, together with other details. The objective of these practice guidelines is to establish standard policies on issues in clinical areas related to the management of uterine corpus cancer based on the findings in published papers to date and the consensus of experts as a KSGO Consensus Statement.
[Mh] Termos MeSH primário: Adenossarcoma/terapia
Neoplasias do Endométrio/terapia
Neoplasias Uterinas/terapia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
República da Coreia
Sociedades Médicas
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161129
[St] Status:MEDLINE
[do] DOI:10.3802/jgo.2017.28.e12


  7 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27769260
[Au] Autor:Krentel H; De Wilde RL
[Ad] Endereço:Clinic of Obstetrics and Gynecology, St. Anna Hospital, Herne, Germany. krentel@cegpa.org.
[Ti] Título:Submucous uterine adenosarcoma-minimally invasive treatment.
[So] Source:World J Surg Oncol;14(1):271, 2016 Oct 21.
[Is] ISSN:1477-7819
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Uterine adenosarcomas are rare malignant gynaecological tumours. Due to its submucous localization, they can be easily confound with benign tumours like endometrial polyps or submucous myomas. However, the treatment of uterine adenosarcomas requires an oncologic surgical approach. CASE PRESENTATION: In the following case report, we present the minimally invasive treatment of a uterine adenosarcoma by hysteroscopy and laparoscopy in a 37-year-old patient and discuss the special role of hysteroscopy in such cases. CONCLUSIONS: In case of unknown or suspect intrauterine tumours, a diagnostic and operative hysteroscopy with biopsy could be realized prior to laparoscopic hysterectomy especially when the use of a laparoscopic electric morcellation is planned. Thus, a correct oncologic approach can be guaranteed if an adenosarcoma is diagnosed. TRIAL REGISTRATION: ISRCTN.
[Mh] Termos MeSH primário: Adenossarcoma/cirurgia
Histerectomia/métodos
Histeroscopia/métodos
Neoplasias Uterinas/cirurgia
[Mh] Termos MeSH secundário: Actinas/metabolismo
Adenossarcoma/diagnóstico por imagem
Adenossarcoma/metabolismo
Adenossarcoma/patologia
Adulto
Biópsia
Feminino
Seres Humanos
Histeroscopia/instrumentação
Queratinas/metabolismo
Estadiamento de Neoplasias
Neprilisina/metabolismo
Ovariectomia
Ovário/patologia
Salpingectomia
Ultrassonografia
Neoplasias Uterinas/diagnóstico por imagem
Neoplasias Uterinas/metabolismo
Neoplasias Uterinas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Actins); 0 (cytokeratin MNF116, human); 68238-35-7 (Keratins); EC 3.4.24.11 (Neprilysin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161023
[St] Status:MEDLINE


  8 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27718181
[Au] Autor:Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
[Ad] Endereço:Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. mjnathenson@gmail.com.
[Ti] Título:Uterine Adenosarcoma: a Review.
[So] Source:Curr Oncol Rep;18(11):68, 2016 Nov.
[Is] ISSN:1534-6269
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Adenosarcomas are rare malignancies of the female genital tract, accounting for approximately 5 % of uterine sarcomas. Occasionally, adenosarcoma occurs in the ovaries or in extra-uterine tissue, which may be related to endometriosis. These tumors are characterized by benign epithelial elements and a malignant mesenchymal component. Pathologic diagnosis is dependent on the identification of the characteristic morphologic features. The most common immunohistochemical markers for adenosarcoma are CD10 and WT1, but these are not specific. The most frequent presenting symptom is abnormal uterine bleeding. The majority of patients present with stage I disease, with a 5-year overall survival of 60 to 80 %. Survival is influenced by the presence of myometrial invasion, sarcomatous overgrowth, lymphovascular invasion, necrosis, and the presence of heterologous elements including rhabdomyoblastic differentiation. Patients with sarcomatous overgrowth have significantly increased risk of recurrence 23 versus 77 % and decreased 5-year overall survival 50 to 60 %. Standard of care treatment is total hysterectomy with bilateral salpingo-oophorectomy without lymphadenectomy, as the incidence of lymph node metastasis is rare. Retrospective data does not support the use of adjuvant pelvic radiotherapy in uterine adenosarcomas as no survival benefit is seen. Insufficient data exists to recommend routinely neoadjuvant or adjuvant chemotherapy for uterine adenosarcomas. Limited evidence exists for the role of hormonal therapy in uterine adenosarcomas. The PIK3/AKT/PTEN pathway is mutated in ∼70 % of adenosarcomas, and this may represent a possible therapeutic target. This article reviews the current state of knowledge concerning uterine adenosarcoma and discusses the management of this rare tumor.
[Mh] Termos MeSH primário: Adenossarcoma/terapia
Neoplasias Uterinas/terapia
[Mh] Termos MeSH secundário: Adenossarcoma/patologia
Feminino
Seres Humanos
Prognóstico
Neoplasias Uterinas/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161009
[St] Status:MEDLINE


  9 / 271 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27465834
[Au] Autor:Levy RA; Kumarapeli AR; Spencer HJ; Quick CM
[Ad] Endereço:University of Arkansas for Medical Sciences, Department of Pathology, Slot 517, 4301 West Markham St. Little Rock, AR 72205, United States. Electronic address: RALevy@uams.edu.
[Ti] Título:Cervical polyps: Is histologic evaluation necessary?
[So] Source:Pathol Res Pract;212(9):800-3, 2016 Sep.
[Is] ISSN:1618-0631
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to examine a series of clinically identified cervical polyps and determine the incidence of significant histologic and concurrent cytologic findings. METHODS: Consecutive cervical polyps from January 2000 through September 2012 were retrieved from the hospital laboratory information system. Histologic evaluation of these polyps was performed, followed by a chart review of clinical findings and correlation with the immediately prior or concurrently collected cervical Papanicolaou (Pap) test results, when available. RESULTS: A total of 369 cervical polyps were identified and reviewed. The patient ages ranged from 18 to 87 years (mean 46.5years). Eight polyps demonstrated squamous dysplasia (6 Cervical Intraepithelial Neoplasia/CIN I, and 2 CIN II/III), while 6 had malignant or atypical/potentially malignant features (2 adenosarcoma, 2 atypical polyps concerning for Mullerian adenosarcoma, 1 endometrioid endometrial adenocarcinoma and 1 adenocarcinoma in-situ). An increased incidence of atypical squamous cells of undetermined significance (ASCUS) and atypical glandular cells not otherwise specified (AGC NOS) Pap diagnoses (12.7% and 6.1%, respectively) was found in women with benign polyps on biopsy. DISCUSSION: We demonstrated a higher rate of clinically significant histologic findings in cervical polyps (14 of 369 cases, 3.7%) compared to previously reported studies. The increase in ASCUS and AGC Pap results was most likely related to reactive and inflammatory changes present in benign polyps. Our results suggest that removal of all cervical polyps with subsequent histologic review is warranted.
[Mh] Termos MeSH primário: Adenocarcinoma/patologia
Adenossarcoma/patologia
Neoplasia Intraepitelial Cervical/patologia
Colo do Útero/patologia
Pólipos/patologia
Displasia do Colo do Útero/patologia
Neoplasias do Colo do Útero/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170323
[Lr] Data última revisão:
170323
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160729
[St] Status:MEDLINE


  10 / 271 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27139896
[Au] Autor:Gardella B; Bogliolo S; Dominoni M; Zanellini F; Cassani C; Musacchi V; Bertone A; Babilonti L; Spinillo A
[Ad] Endereço:a Departments of Obstetrics and Gynecology , University of Pavia. Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.
[Ti] Título:Role of dacarbazine in the treatment of recurrent mullerian adenosarcoma with sarcomatous overgrowth: Our experience.
[So] Source:J Obstet Gynaecol;36(7):886-887, 2016 Oct.
[Is] ISSN:1364-6893
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Adenossarcoma
Dacarbazina/administração & dosagem
Histerectomia
Excisão de Linfonodo/métodos
Recidiva Local de Neoplasia
Ovariectomia/métodos
Neoplasias Uterinas
[Mh] Termos MeSH secundário: Adenossarcoma/patologia
Adenossarcoma/fisiopatologia
Adenossarcoma/cirurgia
Idoso
Antineoplásicos Alquilantes/administração & dosagem
Biópsia/métodos
Feminino
Seres Humanos
Histerectomia/efeitos adversos
Histerectomia/métodos
Histeroscopia/métodos
Recidiva Local de Neoplasia/diagnóstico
Recidiva Local de Neoplasia/tratamento farmacológico
Recidiva Local de Neoplasia/patologia
Estadiamento de Neoplasias
Pelve
Resultado do Tratamento
Ultrassonografia/métodos
Neoplasias Uterinas/patologia
Neoplasias Uterinas/fisiopatologia
Neoplasias Uterinas/cirurgia
Útero/diagnóstico por imagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 7GR28W0FJI (Dacarbazine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170620
[Lr] Data última revisão:
170620
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160504
[St] Status:MEDLINE



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde